Manitol Hztm (Mannitol)

Mannitol is filtered by the kidneys but not reabsorbed, creating an osmotic gradient that pulls water into the tubular lumen. This increases urine output and reduces fluid volume in the brain and eye. The resulting osmotic shift also helps to lower intracranial and intra‑ocular pressures, providing therapeutic benefit in emergencies.

The specific dose of Manitol Hztm is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Dosage regimens vary widely, and the prescriber will calculate the appropriate infusion rate and total amount required for each individual case.

Safety data for Mannitol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers will assess the risk‑benefit ratio before prescribing, and breastfeeding mothers should discuss possible exposure with their physician.

To order Manitol Hztm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Mannitol is a widely used osmotic diuretic with a rapid onset of action when given intravenously. Compared with other agents such as hypertonic saline, Mannitol provides both diuretic and pressure‑reducing effects, making it suitable for cerebral edema and acute glaucoma. Choice of agent depends on the clinical scenario, patient tolerance, and physician preference.

Manitol Hztm should be stored at 2‑8 °C in a refrigerator, protected from light. The solution must not be frozen or shaken. Before administration, inspect the vial for particulate matter or discoloration and use aseptic technique to maintain sterility.

Manitol Hztm is administered intravenously, typically as a slow infusion over several minutes to hours, depending on the indication. The infusion rate and total dose are set by the prescribing clinician, and vital signs should be monitored throughout the administration.

Serious risks include acute renal failure, especially in patients with pre‑existing kidney disease, severe electrolyte imbalances that can cause cardiac arrhythmias, pulmonary edema from fluid overload, and rare allergic reactions such as anaphylaxis. Continuous monitoring of renal function, electrolytes, and fluid status is essential.

Mannitol Hztm is contraindicated in patients with active intracranial bleeding, severe pulmonary edema, anuria, or known hypersensitivity to Mannitol. Caution is also advised for individuals with severe renal impairment, uncontrolled electrolyte disturbances, or those receiving other osmotic agents.